A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannan
- 21 September 2022
- journal article
- research article
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 222 (Pt A) , 661-670
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Beijing Municipality (M21013)
- National Key Research and Development Program of China (2018YFA0900804)
- National Natural Science Foundation of China (31970875, 82271869)
This publication has 45 references indexed in Scilit:
- An aluminium adjuvant in a vaccine is an acute exposure to aluminiumJournal of Trace Elements in Medicine and Biology, 2020
- Recombinant flagellins with deletions in domains D1, D2, and D3: Characterization as novel immunoadjuvantsVaccine, 2019
- Mannosylated T/Tn with Freund’s adjuvant induces cellular immunityInternational Journal of Immunopathology and Pharmacology, 2017
- Clinical toxicity of antibody drug conjugates: a meta-analysis of payloadsInvestigational New Drugs, 2017
- Bacterial flagellin—a potent immunomodulatory agentExperimental & Molecular Medicine, 2017
- Potent Antigen-Adjuvant Delivery System by Conjugation of Mycobacterium tuberculosis Ag85B-HspX Fusion Protein with Arabinogalactan-Poly(I:C) ConjugateBioconjugate Chemistry, 2016
- Beyond antigens and adjuvants: formulating future vaccinesJournal of Clinical Investigation, 2016
- Deletion of Flagellin’s Hypervariable Region Abrogates Antibody-Mediated Neutralization and Systemic Activation of TLR5-Dependent ImmunityThe Journal of Immunology, 2008
- GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectivesExpert Review of Vaccines, 2007
- Characterization and immunogenicity of meningococcal group C conjugate vaccine prepared using hydrazide-activated tetanus toxoidVaccine, 2007